Elastase modifies bleomycin-induced pulmonary fibrosis in mice

Trajano, Larissa Alexsandra da Silva Neto; Trajano, Eduardo Tavares Lima; Lanzetti, Manuella; Mendonça, Morena Scopel Amorim; Guilherme, Rafael F.; Figueiredo, Rodrigo T.; Benjamim, Cláudia F.; Monte‐Alto‐Costa, Andréa; Pôrto, Luís Cristóvão

doi:10.1016/j.acthis.2015.12.010

Cited by 6 publications

(3 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is particularly the case for CPFE, for which limited animal models that recapitulate its cardinal features (fibrotic deposition, airspace enlargement and PH) have been described. Features of CPFE have been modeled by treating mice with both the fibrotic agent bleomycin and elastase to induce airspace enlargement (Cattani-Cavalieri et al, 2017; Trajano et al, 2016). Experiments have also been performed treating cigarette-smoke exposed mice with bleomycin or herpesvirus, leading to airspace enlargement and fibrotic matrix deposition (Zhang et al, 2017).…”

Section: Discussionmentioning

confidence: 99%

Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema

Collum

Molina

Hanmandlu

et al. 2019

Disease Models &Amp; Mechanisms

View full text Add to dashboard Cite

Combined pulmonary fibrosis and emphysema (CPFE) is a syndrome that predominantly affects male smokers or ex-smokers and it has a mortality rate of 55% and a median survival of 5 years. Pulmonary hypertension (PH) is a frequently fatal complication of CPFE. Despite this dismal prognosis, no curative therapies exist for patients with CPFE outside of lung transplantation and no therapies are recommended to treat PH. This highlights the need to develop novel treatment approaches for CPFE. Studies from our group have demonstrated that both adenosine and its receptor ADORA2B are elevated in chronic lung diseases. Activation of ADORA2B leads to elevated levels of hyaluronan synthases (HAS) and increased hyaluronan, a glycosaminoglycan that contributes to chronic lung injury. We hypothesize that ADORA2B and hyaluronan contribute to CPFE. Using isolated CPFE lung tissue, we characterized expression levels of ADORA2B and HAS. Next, using a unique mouse model of experimental lung injury that replicates features of CPFE, namely airspace enlargement, PH and fibrotic deposition, we investigated whether 4MU, a HAS inhibitor, was able to inhibit features of CPFE. Increased protein levels of ADORA2B and HAS3 were detected in CPFE and in our experimental model of CPFE. Treatment with 4MU was able to attenuate PH and fibrosis but not airspace enlargement. This was accompanied by a reduction of HAS3-positive macrophages. We have generated pre-clinical data demonstrating the capacity of 4MU, an FDA-approved drug, to attenuate features of CPFE in an experimental model of chronic lung injury. .

show abstract

Section: Discussionmentioning

confidence: 99%

Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema

Collum

Molina

Hanmandlu

et al. 2019

Disease Models &Amp; Mechanisms

View full text Add to dashboard Cite

show abstract

“…It is frequently associated with idiopathic interstitial pneumonia, collagen diseases and so on (1)(2)(3)(4). To date, the prognosis of patients with diffuse pulmonary fibrosis is poor because of lack of effective treatments (1,3,5).…”

Section: Introductionmentioning

confidence: 99%

Medication regularity of pulmonary fibrosis treatment by contemporary traditional Chinese medicine experts based on data mining

Zhang

Liu

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Background: Treatment of pulmonary fibrosis by traditional Chinese medicine (TCM) has accumulated important experience. Our interest is in exploring the medication regularity of contemporary Chinese medical specialists treating pulmonary fibrosis.Methods: Through literature search, medical records from TCM experts who treat pulmonary fibrosis, which were published in Chinese and English medical journals, were selected for this study. As the object of study, a database was established after analysing the records. After data cleaning, the rules of medicine in the treatment of pulmonary fibrosis in medical records of TCM were explored by using data mining technologies such as frequency analysis, association rule analysis, and link analysis. Results: A total of 124 medical records from 60 doctors were selected in this study; 263 types of medicinals were used a total of 5,455 times; the herbs that were used more than 30 times can be grouped into 53 species and were used a total of 3,681 times. Using main medicinals cluster analysis, medicinals were divided into qi-tonifying, yin-tonifying, blood-activating, phlegm-resolving, cough-suppressing, panting-calming, and ten other major medicinal categories. According to the set conditions, a total of 62 drug compatibility rules have been obtained, involving mainly qi-tonifying, yin-tonifying, blood-activating, phlegm-resolving, qidescending, and panting-calming medicinals, as well as other medicinals used in combination. Conclusions:The results of data mining are consistent with clinical practice and it is feasible to explore the medical rules applicable to the treatment of pulmonary fibrosis in medical records of TCM by data mining.

show abstract

“…After the excessive accumulation of extracellular matrix (ECM) in affected lungs, which presents as dyspnea and asthma, the lung architecture disorders and diffuse inflammation led to a progressive, fibrosing, interstitial pneumonia. [7,8] The superabundant inflammation is involved in ECM and results in imbalance between the synthesis and degradation of ECM. To date, treatments targeting these events, which include glucocorticoids, cytokine inhibitors, antifibrotic agents, and lung transplantation or else, may promote the effect of IPF.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of TCM therapy of tonifying lung–kidney's Qi-deficiency in a case of idiopathic pulmonary fibrosis

et al. 2019

View full text Add to dashboard Cite

Rationale: Idiopathic pulmonary fibrosis (IPF) is a special form of spontaneous, chronic, progressive interstitial fibrotic pneumonia of unknown cause, and treatments for IPF have shown a poor prognosis. This study reports a new treatment, traditional Chinese medicine (TCM) therapy, for tonifying Qi-deficiency of lung–kidney in a 64-year-old patient with IPF. Patient concerns: A 64-year-old man, who complained of cough and asthma, was diagnosed as IPF with mild impairment in lung function by thoracic high-resolution computed tomography and pulmonary function test. He received an 18-month N-acetylcysteine monotherapy but had no improvement in lung function. Diagnoses: IPF with mild impairment in lung function was diagnosed. Interventions: The Chinese herbal medicine composition was decocted in 300 ml water for oral administration with 150 ml decoction twice daily in June 2017. Outcomes: The pulmonary function test showed that diffusing capacity for carbon monoxide had increased to 81% of predicted back to normal after 2-month TCM monotherapy. And diffusing capacity for carbon monoxide had increased to 89% of predicted, and forced expiratory volume in 1 s/forced vital capacity ratio increased to 92% at 14-month follow-up. No adverse events occurred during the 14 months of therapy and observation. Lessons: The treatment by TCM therapy of tonifying lung–kidney's Qi-deficiency for IPF can improve the pulmonary function and reverse disease progression; it may be considered as a complementary treatment for IPF with mild-to-moderate impairment. However, the insights provided in this case report require further exploration and verification.

show abstract

Elastase modifies bleomycin-induced pulmonary fibrosis in mice

Cited by 6 publications

References 60 publications

Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema

Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema

Medication regularity of pulmonary fibrosis treatment by contemporary traditional Chinese medicine experts based on data mining

Efficacy of TCM therapy of tonifying lung–kidney's Qi-deficiency in a case of idiopathic pulmonary fibrosis

Contact Info

Product

Resources

About